Login| Sign Up| Help| Contact|

Patent Searching and Data


Title:
NK1 RECEPTOR ANTAGONIST
Document Type and Number:
WIPO Patent Application WO/2017/099049
Kind Code:
A1
Abstract:
The present invention addresses the problem of providing a novel compound which has NK1 receptor antagonistic activity and which is useful in the prevention and treatment of nausea and vomiting accompanying the administration of antineoplastic agents. The present invention pertains to a compound represented by formula (I) (in the formula, W represents a fluorine atom or the like, ring A represents a cycloalkyl or the like, X1 represents CH or N, R represents a methyl group or the like, Y represents a number from 0 to 2, and U1, U2, and U3 each independently represent a single bond or the like), or a pharmacologically acceptable salt thereof. This compound or pharmacologically acceptable salt thereof has excellent NK1 receptor antagonistic activity and is useful as a prophylactic or therapeutic agent for nausea and vomiting accompanying the administration of antineoplastic agents.

Inventors:
MIYAGI TAKASHI (JP)
KOBAYASHI MASAHIRO (JP)
NISHIMURA TOSHIHIRO (JP)
Application Number:
PCT/JP2016/086150
Publication Date:
June 15, 2017
Filing Date:
December 06, 2016
Export Citation:
Click for automatic bibliography generation   Help
Assignee:
KISSEI PHARMACEUTICAL (JP)
International Classes:
C07D241/04; A61K31/451; A61K31/495; A61P1/08; C07D211/62; C07D401/06
Domestic Patent References:
WO2015170693A12015-11-12
WO2008133344A22008-11-06
WO2015068744A12015-05-14
WO2010007032A12010-01-21
WO2016021562A12016-02-11
WO2008133344A22008-11-06
Foreign References:
JP2006045208A2006-02-16
JP2004143139A2004-05-20
JP2003511377A2003-03-25
US20020091265A12002-07-11
JP2003511377A2003-03-25
JP2006045208A2006-02-16
JP2007197428A2007-08-09
Other References:
PELLEGATTI, MARIO ET AL.: "Disposition and Metabolism of Radiolabeled Casopitant in Humans", DRUG METABOLISM AND DISPOSITION, vol. 37, no. 8, 2009, pages 1635 - 1645, XP055598999, ISSN: 0090-9556
See also references of EP 3388423A4
P. J. HESKETH ET AL., EUROPEAN JOURNAL OF CANCER, vol. 39, 2003, pages 1074 - 1080
TONI M. DANDO ET AL., DRUGS, vol. 64, no. 7, 2004, pages 777 - 794
JACQUELINE B. MCCREA ET AL., CLINICAL PHARMACOLOGY & THERAPEUTICS, vol. 74, no. 1, 2003, pages 17 - 24
Attorney, Agent or Firm:
YANAGI, Nobuko et al. (JP)
Willow Nobuko (JP)
Download PDF: